FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:67-68 January 1, 2004 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Corey, L. PubMed Citation

One of the main lessons of antiviral-drug therapy is that the drugs that inhibit viral replication are frequently more effective at preventing viral disease than they are at treating established disease. Acyclovir, for example, when taken on a daily basis, will prevent outbreaks of recurrent genital herpes infection, but when it is taken early to treat an episode of recurrent genital herpes, the result is a shortening of the course of disease by only one day — a marginal clinical benefit.¹ Ganciclovir, the mainstay of therapy for cytomegalovirus (CMV) disease, has a similar effect. This drug was first used in . . . [Full Text of this Article]

Source Information

From the Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.